跳至主要内容
临床试验/jRCT2080224670
jRCT2080224670已完成2 期

Phase II trial of the combination of SPM-011 and BNCT System for recurrent malignant glioma

STELLA PHARMA CORPORATION1 个研究点目标入组 24 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
24
试验地点
1
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
干预模型
Multi-center, open label, single armed study
主要目的
Treatment Purpose

入排标准

年龄范围
20age old over 至 74age old under(—)
性别
All

入选标准

  • Karnofsky performance status of >=60
  • Patients treated with temozolomide and radiation therapy. Patients with relapse or exacerbation of malignant glioma by CT or MRI
  • Patients who underwent radiotherapy with a total dose of 50 Gy - 65 Gy with fractional radiation of about 2 Gy per day for the target lesion site
  • Patients having measurable lesion according to RANO criteria

排除标准

  • Patients with active multiple primary cancers
  • Patients with extracranial metastasis
  • Patients with meningeal or intrathecal dissemination or discontinuous two or more tumor lesions
  • Patients treated with Bevacizumab

结局指标

主要结局

-

efficacy 1-year survival rate

次要结局

未报告次要终点

研究者

研究点 (1)

Loading locations...

相似试验